Stakeholders Watching Controversial Personal Care Products Safety Act
This article was originally published in The Rose Sheet
The Personal Care Products Act has elicited a mixed reaction from cosmetics stakeholders; as for its prospects, the bill could be "dead on arrival," or it just might pass, according to industry veteran David Steinberg. "The Rose Sheet" is tracking the bill's progress with an updating infographic at therosesheet.com.
You may also be interested in...
The draft Personal Care Products Safety Act’s safety substantiation requirements – including statements from responsible persons attesting to product safety – are hazily defined and could pose liability risks, in addition to burdens for small companies in particular, EAS consultant John Bailey says. For these reasons and others, the former FDAer is skeptical that industry will support the bill in its current form.
Small-business trade group the Independent Cosmetic Manufacturers and Distributors says the Personal Care Products Safety Act would place an undue burden on small businesses and fails to address national uniformity issues. In an interview with “The Rose Sheet,” ICMAD President and CEO Pam Busiek discussed the group’s opposition to the bill and suggested that 2012’s Cosmetic Safety Amendments Act would have been a better starting point for legislation.
Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.